The National Science Foundation (NSF) awarded a $275,000 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Islex Therapeutics, LLC. The project aims to develop antibody therapeutics for the treatment of Stage 3 (clinically overt) Type 1 Diabetes (T1D). The research will focus on harnessing the synergistic effects of autoimmune protection via a beta-cell masking antibody, insulin supplementation, and targeted delivery of mitogenic drugs to the pancreatic islet. The anticipated outcome is the development of a novel therapeutic product that could revolutionize the treatment landscape for Stage 3 T1D, with potential future expansion to other forms of severe beta-cell loss. Subawards are planned under this project.
Generated 1/28/25, 9:15 AM